结合生物信息学分析构建乳腺癌预后ceRNA网络景观,探索影响药物反应的基因

IF 1.2 4区 医学 Q4 CHEMISTRY, MEDICINAL
Mahboubeh Sadeghi, Claudia Cava, Pegah Mousavi, Soudabeh Sabetian, Mohammad Hossein Morowvat
{"title":"结合生物信息学分析构建乳腺癌预后ceRNA网络景观,探索影响药物反应的基因","authors":"Mahboubeh Sadeghi, Claudia Cava, Pegah Mousavi, Soudabeh Sabetian, Mohammad Hossein Morowvat","doi":"10.2174/0115701808255183230922110002","DOIUrl":null,"url":null,"abstract":"Background:: Breast cancer accounts for 30% of all new female cancers yearly. Bioinformatics serves us to find new biomarkers and facilitate future experimental research. Exploring a distinct network of competing endogenous RNA (ceRNA) that includes potential prognostic, diagnostic, and therapeutic biomarkers is captivating. Methods:: Differentially expressed lncRNAs, mRNAs, and miRNAs were collected using Gene Expression Omnibus datasets. DEGs were validated based on TCGA. Functional analysis and pathway activity were also done. Drug sensitivity analyses were done, and IC50 vs. gene expression plots were depicted. Results:: A total of 696 mRNAs, 48 lncRNAs, and, 43 miRNAs were identified to have significant differential expression in cancerous breast tissue than normal breast tissue samples. Functional analysis showed significant pathway enrichments in cancer. We found that 13 individual genes, lncRNAs, and miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454 were significantly predictive of poor overall survival and AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3 and, hsa-miR-29c were associated with favorable overall survival. We reached a set of five genes (EGR1, NFIB, TGFBR3, SMARCA4, and MCM2) that exhibit altered expression patterns in breast cancer, resulting in increased susceptibility of cancer cells to certain drug treatments. Conclusion:: We successfully made a unique ce-network, providing new clues to understand the regulatory functions of non-coding RNAs (miRNAs and lncRNAs) in the pathogenesis and prognosis of breast cancer and will facilitate further experimental studies to develop new biomarkers in the diagnosis, prognosis and, therapy of breast cancer. result: Functional analysis showed significant pathway enrichments in cancer, and we found that 13 individual genes, lncRNAs, and miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454 were significantly predictive of poor overall survival and AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3 and, hsa-miR-29c were associated with favorable overall survival. other: None","PeriodicalId":18059,"journal":{"name":"Letters in Drug Design & Discovery","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Construction of Prognostic ceRNA Network Landscape in Breast Cancer to Explore Impacting Genes on Drug Response by Integrative Bioinformatics Analysis\",\"authors\":\"Mahboubeh Sadeghi, Claudia Cava, Pegah Mousavi, Soudabeh Sabetian, Mohammad Hossein Morowvat\",\"doi\":\"10.2174/0115701808255183230922110002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background:: Breast cancer accounts for 30% of all new female cancers yearly. Bioinformatics serves us to find new biomarkers and facilitate future experimental research. Exploring a distinct network of competing endogenous RNA (ceRNA) that includes potential prognostic, diagnostic, and therapeutic biomarkers is captivating. Methods:: Differentially expressed lncRNAs, mRNAs, and miRNAs were collected using Gene Expression Omnibus datasets. DEGs were validated based on TCGA. Functional analysis and pathway activity were also done. Drug sensitivity analyses were done, and IC50 vs. gene expression plots were depicted. Results:: A total of 696 mRNAs, 48 lncRNAs, and, 43 miRNAs were identified to have significant differential expression in cancerous breast tissue than normal breast tissue samples. Functional analysis showed significant pathway enrichments in cancer. We found that 13 individual genes, lncRNAs, and miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454 were significantly predictive of poor overall survival and AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3 and, hsa-miR-29c were associated with favorable overall survival. We reached a set of five genes (EGR1, NFIB, TGFBR3, SMARCA4, and MCM2) that exhibit altered expression patterns in breast cancer, resulting in increased susceptibility of cancer cells to certain drug treatments. Conclusion:: We successfully made a unique ce-network, providing new clues to understand the regulatory functions of non-coding RNAs (miRNAs and lncRNAs) in the pathogenesis and prognosis of breast cancer and will facilitate further experimental studies to develop new biomarkers in the diagnosis, prognosis and, therapy of breast cancer. result: Functional analysis showed significant pathway enrichments in cancer, and we found that 13 individual genes, lncRNAs, and miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454 were significantly predictive of poor overall survival and AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3 and, hsa-miR-29c were associated with favorable overall survival. other: None\",\"PeriodicalId\":18059,\"journal\":{\"name\":\"Letters in Drug Design & Discovery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Letters in Drug Design & Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115701808255183230922110002\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Drug Design & Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115701808255183230922110002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:乳腺癌占每年新发女性癌症的30%。生物信息学为我们发现新的生物标志物和促进未来的实验研究提供了帮助。探索一个独特的竞争内源性RNA (ceRNA)网络,包括潜在的预后,诊断和治疗生物标志物是迷人的。方法:使用Gene Expression Omnibus数据库收集差异表达的lncrna、mrna和mirna。基于TCGA对deg进行验证。并进行了功能分析和途径活性分析。进行药物敏感性分析,绘制IC50与基因表达图。结果:共鉴定出696个mrna、48个lncrna和43个mirna在癌性乳腺组织中与正常乳腺组织样本有显著差异表达。功能分析显示在癌症中有显著的通路富集。我们发现13个个体基因,lncRNAs和miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454显著预测较差的总生存,AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3和hsa-miR-29c与较好的总生存相关。我们发现了5个基因(EGR1、NFIB、TGFBR3、SMARCA4和MCM2)在乳腺癌中表现出改变的表达模式,导致癌细胞对某些药物治疗的易感性增加。结论:我们成功构建了独特的ce-网络,为了解非编码rna (miRNAs和lncRNAs)在乳腺癌发病和预后中的调控功能提供了新的线索,为进一步的实验研究开发新的乳腺癌诊断、预后和治疗生物标志物提供了便利。结果:功能分析显示癌症中有显著的通路富集,我们发现13个个体基因,lncRNAs和miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454显著预测较差的总生存,AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3和hsa-miR-29c与良好的总生存相关。其他:无
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Construction of Prognostic ceRNA Network Landscape in Breast Cancer to Explore Impacting Genes on Drug Response by Integrative Bioinformatics Analysis
Background:: Breast cancer accounts for 30% of all new female cancers yearly. Bioinformatics serves us to find new biomarkers and facilitate future experimental research. Exploring a distinct network of competing endogenous RNA (ceRNA) that includes potential prognostic, diagnostic, and therapeutic biomarkers is captivating. Methods:: Differentially expressed lncRNAs, mRNAs, and miRNAs were collected using Gene Expression Omnibus datasets. DEGs were validated based on TCGA. Functional analysis and pathway activity were also done. Drug sensitivity analyses were done, and IC50 vs. gene expression plots were depicted. Results:: A total of 696 mRNAs, 48 lncRNAs, and, 43 miRNAs were identified to have significant differential expression in cancerous breast tissue than normal breast tissue samples. Functional analysis showed significant pathway enrichments in cancer. We found that 13 individual genes, lncRNAs, and miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454 were significantly predictive of poor overall survival and AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3 and, hsa-miR-29c were associated with favorable overall survival. We reached a set of five genes (EGR1, NFIB, TGFBR3, SMARCA4, and MCM2) that exhibit altered expression patterns in breast cancer, resulting in increased susceptibility of cancer cells to certain drug treatments. Conclusion:: We successfully made a unique ce-network, providing new clues to understand the regulatory functions of non-coding RNAs (miRNAs and lncRNAs) in the pathogenesis and prognosis of breast cancer and will facilitate further experimental studies to develop new biomarkers in the diagnosis, prognosis and, therapy of breast cancer. result: Functional analysis showed significant pathway enrichments in cancer, and we found that 13 individual genes, lncRNAs, and miRNAs, CDC6, ERBB2, EZR, HELLS, MAPK13, MCM2, MMP1, SLC7A5, TINCR, TRIP13, hsa-miR-376a, hsa-miR-21, hsa-miR-454 were significantly predictive of poor overall survival and AKAP12, CXCL12, FGF2, IRS2, LINC00342, LINC01140, MEG3, MIR250HG, NAV3, NDRG2, NEAT1, TGFBR3 and, hsa-miR-29c were associated with favorable overall survival. other: None
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.80
自引率
10.00%
发文量
245
审稿时长
3 months
期刊介绍: Aims & Scope Letters in Drug Design & Discovery publishes letters, mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信